Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Spotlight reports on this and some of the ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

Although modern antiretroviral therapy is highly effective and well tolerated, new drugs are needed for people who develop resistance or rare side effects. Drug companies are competing to develop long ...

The HIV Drugs Market is expected to grow steadily from 2025 to 2035, driven by advancements in antiretroviral therapy and increasing global awareness initiatives. Rising HIV prevalence, improved ...

A new formulation of Gilead’s HIV prevention drug, lenacapavir, has shown promise in providing yearlong protection with just one injection. The study, published in The Lancet, evaluated the ...

The early results of trials for two injectable, investigational antiretroviral therapies, VH4524184 and VH4011499, have the ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Latonia Wilkins knows she needs to be on PrEP due to her non-monogamous lifestyle. But the 52-year-old Atlanta mother has ...

As many as 600,000 people could die over the next 10 years in South Africa alone as a result of U.S. funding cuts, study says ...